Pelacarsen |
Catalog No.GC71146 |
Pelacarsen (akcea - Apo (A) - lrx) est un oligonucléotide antisens spécifique du foie qui cible l'apolipoprotéine (A) et réduit la lipoprotéine (b) de 80%, bien toléré.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1637637-70-7
Sample solution is provided at 25 µL, 10mM.
Mice dosed with Pelacarsen at dose levels of 0.3, 1, 3, and 10 mg/kg once weekly for 6 weeks had dose-dependent reductions in target mRNA expression. The model-estimated doses for Pelacarsen that produced 50% of maximum drug-induced inhibitory effect (ED50) for liver apo(a) mRNA and plasma apo(a) protein levels were 0.32 and 0.54 mg/kg/week, respectively.
References:
[1]. Yu RZ, Graham MJ, Post N, et al. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice. Mol Ther Nucleic Acids. 2016;5(5):e317.
[2]. Yu RZ, Gunawan R, Post N, et al. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys. Nucleic Acid Ther. 2016;26(6):372-380.
[3]. Yeang C, et al. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. J Am Coll Cardiol. 2022 Mar 22;79(11):1035-1046.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *